The physiological eects of estrogens are mediated by two intracellular transcription factors, the estrogen receptors (ERs), that regulate transcription of target genes through binding to speci®c DNA target sequences. Here we describe alterations in cellular responses to dierent ER agonists and to the anti-estrogenic compound tamoxifen resulting from co-expression of the two ERs in transient co-transfection experiments. Our results demonstrate that ERb can act as a negative or positive dominant regulator of ER activity. This is manifested through reduced transcriptional activity at low concentrations of estradiol (E 2 ); increased antagonistic eects of tamoxifen on E 2 stimulated activity; and enhanced agonistic action of the phytoestrogenic compound genistein. Furthermore, using chimeric proteins lacking the N-terminal activation function 1 (AF-1), we show that the dierential responses of ERa and ERb to dierent agonists and antagonists are primarily dictated by inherent dierences in the C-terminal ligand-binding domains of the receptors, whereas the magnitude of transcriptional activity is in¯uenced by ERa AF-1, but not ERb AF-1. The ERa AF-1 activity appears to be modulated upon co-expression of both ERs. The alterations in transcriptional activity resulting from co-expression of ERa and ERb are probably due to the formation of a/b heterodimeric complexes. This study demonstrates that co-localization and subsequent heterodimerization of ERa and ERb may result in receptor activity distinct from that of ER homodimers.
Introduction
The estrogen receptors (ERs) belong to a group of ligand-inducible transcription factors known as the nuclear receptor superfamily (Laudet et al., 1992) . Members of the family share several functional and structural similarities such as a variable N-terminus containing a transactivation function (AF-1), a centrally located DNA binding domain (DBD) consisting of two highly conserved zinc ®nger motifs and, Cterminally of the DBD, a region involved in binding of ligand, dimerization and transactivation, referred to as the ligand binding domain (LBD) (Gronemeyer and Laudet, 1995) . The nuclear receptor family includes receptors for estrogens, progestins, androgens, glucocorticoids, mineralocorticoids (Beato et al., 1996) , thyroid hormone, fatty acids and vitamin D3. The majority of nuclear receptor family members consists of a steadily growing number of receptors for which the ligand is unknown, the so called orphan receptors (Mangelsdorf and Evans, 1995) .
Estrogens have long been recognized to be critical for the development, maturation and function of the female reproductive system. Lately the role of estrogens in heart and vascular protection and for maintenance of bone mass has also attracted considerable interest (Farhat et al., 1996) . Studies of ERa knock-out mice have revealed important functions for estrogens also in the male reproductive system (Hess et al., 1997; Lubahn et al., 1993) . Adversely, estrogens have been implicated in development and progression of tumors in breast and endometrium (Ciocca and Fanelli, 1997) . Because of the estrogen-dependent growth of many breast tumors, endocrine therapy with anti-estrogens such as tamoxifen is often successful. However, some tumors become resistant to antiestrogenic treatment possibly re¯ecting changes in ER status within the tumor (Jordan and Morrow, 1999) .
The identi®cation of a second estrogen receptor has added a new dimension to the complexity of estrogen signaling (Kuiper et al., 1996) . The new receptor was named ERb to distinguish it from the previous one, consequently named ERa. Subsequently, human and mouse homologs of ERb were isolated (Mosselman et al., 1996; Pettersson et al., 1997; Tremblay et al., 1997) . ERb displays extensive sequence similarity to ERa, most notable in the DBD where the amino acid identity is 97% whereas the LBD shows an overall 55% similarity to ERa. However, the ligand binding pocket and the ligand dependent activation function (AF-2) show a higher degree of resemblance. Functionally both receptors share several characteristics in that they bind estradiol (E 2 ) and related compounds and recognize and initiate transcription from palindromic DNA sequences referred to as estrogen response elements (ERE) (Kuiper et al., 1996) . ERb has been reported to have weaker transcriptional activity in response to E 2 compared to ERa in transient co-transfection assays in several cell systems (Cowley et al., 1997; Pettersson et al., 1997; Watanabe et al., 1997) . ERb also, in contrast to ERa, fails to show agonistic response to the well known anti-estrogen tamoxifen (Tremblay et al., 1997; Watanabe et al., 1997) . Recently ERa, but not ERb, was demonstrated to bind to and activate transcription from the DNA core element known as an SF1 (Steroidogenic Factor 1) response element, thus demonstrating functional dierences between the ERs also at the DNA binding level (Vanacker et al., 1999) .
The N-terminally located A/B domain, which contains the ligand independent transactivation function AF-1, is poorly conserved between the ERs. The activity of ERa AF-1 has been described as highly cell speci®c, with varying activity depending on cell type (Katzenellenbogen et al., 1996) . Studies using receptor chimeras where the A/B domains of the ERs were interchanged have demonstrated that dierences in transcriptional potency as well as response to antiestrogens rely on the nature of this domain. The activity of the respective AF-1 and AF-2 of the ERs was also found to be in¯uenced by cellular context . We have previously demonstrated the formation of functional heterodimeric complexes between the two ER subtypes (Pettersson et al., 1997) . The importance of heterodimerization as well as several aspects of ERb function are still unclear. A recent study, using mutant ERs with altered DNA binding speci®city which allowed measurement of transcriptional activity induced exclusively by a/b heterodimers, demonstrated that while two functional AF-2's were required for transcriptional activity, activation could occur if only one of the ER subunits within the heterodimer was bound by E 2 , albeit to a lower extent (Tremblay et al., 1999) .
Given the reported dierences between ERa and ERb we wanted to examine functional aspects of coexpression in the presence of receptor agonists and antagonists. Alterations in transcriptional activity resulting from ERa/ERb co-expression were analysed using transient co-transfection assays under carefully monitored conditions.
Results

Co-expression of ERa and ERb negatively influences transcriptional response to low concentrations of E 2
We transiently transfected the human embryonic kidney cell line 293 with a luciferase reporter construct containing two copies of a consensus ERE inserted in front of a minimal thymidine kinase promoter together with expression plasmids encoding human ERa or mouse ERb. The cells were treated with increasing concentrations of 17b-estradiol (E 2 ) for 24 h, harvested and the reporter activity was determined. Maximal reporter activity was obtained within the range of 5 ± 30 ng of both ERa or ERb encoding plasmids respectively (data not shown) under the conditions used, suggesting similar expression levels of each receptor as judged from their transcriptional activity. All subsequent co-expression experiments were carried out within these optimal limits to exclude uncontrollable events such as auto-squelching. ERb consistently induced reporter activity to a lesser degree compared to ERa, reaching approximately 40%, which is in agreement with previous work using the same cell line (Pettersson et al., 1997, Figure 1c , left hand panel and data not shown).
In agreement with previous observations, ERb is poorly activated by E 2 concentrations below 1 nM (Figure 1b) (Barkhem et al., 1998) . In contrast, ERa, reaches approximately 50% activation already at 0.01 nM and shows maximal transcriptional activity at 0.1 nM (Figure 1a) . The poor response of ERb to low concentrations of E 2 was also observed in HeLa and HepG2 cells and is therefore not restricted to the 293 cell line (data not shown). In co-expression experiments, the amount of the ERa-expressing plasmid was kept constant at 10 ng (a concentration within the time limits of maximal transcriptional activity) and increasing quantities of the ERb-expressing plasmid were added in an a : b ratio of 1 : 0.5, 1 : 1 and 1 : 1.5, respectively (5, 10 and 15 ng, equaling a total of 15, 20 and 25 ng, all within the limits of maximal response). Intriguingly, co-expression of ERa and ERb results in a shift in transcriptional potential (Figure 1c) . The maximal magnitude of activity was reminiscent of that of ERa homodimers, but the E 2 concentration required to obtain full activity was shifted in an ERb-dose dependent manner to nanomolar concentrations (compare gray bars of each panel in Figure 1c ). The decrease in transcriptional activity observed at low E 2 -concentrations is not due to overexpression of ERs as we also performed the same series of transfections using increasing amounts of ERaplasmid instead of ERb without detecting any reduction in transcriptional response (Figure 1d) . Moreover, the reduction in reporter gene activity only occurred under conditions where ERb was demonstrated to be poorly activated; at 1 nM E 2 full transcriptional activity was obtained, regardless of the amount of co-transfected ERb (Figure 1c , compare black bars).
Co-expression of ERb with ERa increases the antagonistic effect of tamoxifen
Tamoxifen, an antiestrogenic compound clinically used in endocrine therapy of breast cancer, has long been recognized as a cell and tissue type dependent mixed agonist/antagonist for ERa (Jordan and Morrow, 1999; Katzenellenbogen et al., 1996) . Both ERs bind tamoxifen with comparable anity but a lack of agonistic eect of tamoxifen on ERb has been reported, suggesting a functional dierence between the two receptor subtypes (Tremblay et al., 1997; Watanabe et al., 1997) .
The ability of tamoxifen to antagonize E 2 -induced activity of both ERs was assessed in 293 cells transiently transfected as previously described, and treated with 1 nM E 2 alone, or in combination with increasing concentrations of tamoxifen. As evident from the results shown in Figure 2b tamoxifen is a more potent antagonist of the E 2 -induced activity of ERb compared to ERa (Figure 2a ). Whereas the ligand-induced activity of ERb is inhibited already at 100 nM tamoxifen, this concentration has only a minor antagonistic eect on the transcriptional activity of ERa, and not even 1 mM tamoxifen can completely antagonize the E 2 -induced activity of ERa. This is in agreement with the described non-agonistic eect of tamoxifen on the ERb subtype. The pronounced antiestrogenic eect of tamoxifen on ERb homodimers suggested that ERa/ERb heterodimers may be more strongly antagonized by tamoxifen than ERa homodimers.
To test this hypothesis we studied the eect of coexpression of both ERs under the same conditions as in Figure 1c . The maximal level of activation was not altered when the amount of ERa was kept constant, but the presence of ERb induced an increased antagonistic eect of tamoxifen in a dose-dependent manner, whereas the response to E 2 alone was intact at all concentrations of co-expressed ERb (Figure 2c , compare gray bars to black and striped bars respectively). Increasing the concentration of transfected ERa, instead of ERb did not result in any change of tamoxifen antagonism (data not shown).
ERb promotes the agonistic effect of genistein
Given the observations that ERb negatively in¯uenced the transcriptional activity in cells where ERa and ERb were co-expressed at low E 2 concentrations or in the presence of tamoxifen, we wanted to investigate whether ERa would reciprocally inhibit transcriptional activity in the presence of an ERb selective ligand. Previous studies have indicated that the iso¯avonoid genistein shows a higher anity for ERb (Barkhem et al., 1998; Kuiper et al., 1997) . 293 cells were cotransfected as before with the ERE-reporter plasmid and ERa or ERb expressing plasmids and treated with increasing amounts of genistein. The results were compared to reporter activity at 1 nM E 2 ( Figure  3a ,b). At 20 nM genistein, ERb reaches approximately 80% of the activity obtained at 1 nM E 2 ( Figure 3b) . In contrast, ERa shows almost no activity at this concentration ( Figure 3a ). Both receptors are fully active at 200 nM of genistein as judged by comparison with E 2 . Genistein acts as a super-agonist for both ER subtypes at 2 mM resulting in more than 200% of maximal activity obtained with E 2 , which could however be due to the ability of genistein at high concentrations to modulate protein kinase signaling pathways that may alter the phosphorylation status of the ERs. These observations are inconsistent with a study carried out with 293 cells stably expressing ERa or ERb where genistein was described as acting as a partial agonist in the ERb expressing cells albeit with a selective anity for the b receptor (Barkhelm et al., Figure 1 Higher concentrations of E 2 is required for ecient transcriptional activity in the presence of ERb alone or ERb coexpressed with ERa. 293 cells were transiently transfected with a luciferase reporter gene construct containing two copies of a consensus ERE and expression plasmids for ERa or ERb. The transcriptional response to dierent concentrations of E 2 by ERa (a, gray bars) or ERb (b, black bars) was determined. Data is presented as % activity+s.d., where reporter activity obtained at 1 nM of E 2 was arbitrarily set to 100 for each receptor. All experiments were done in duplicates at least three times. (c) Eects of coexpression of ERb together with ERa on response to E 2 . Ratio of expression plasmids a : b were 1 : 0.5, 1 : 1, or 1 : 1.5 (panels 2, 3, and 4, respectively). (d) Control experiment using increasing amount of ERa expression plasmid under the same conditions as in b. Data is presented as mean of fold induction+s.d. from at least three independent experiments performed in duplicates. Activity of reporter plasmid alone without hormone treatment was arbitrarily set to 1
Consequences of ERa/ERb co-expression K Pettersson et al 1998). In the mentioned study the cells were treated with genistein for 72 h, whereas we measured activity after 24 h, which could account for the observed discrepancy.
We next performed co-expression experiments with both ERs in the presence of genistein (Figure 3c) . Surprisingly, the reporter activity at 20 nM genistein was higher when both receptors were co-expressed than what was observed with either receptor alone. The activity of ERa alone at this concentration is marginally above basal levels but clearly ERa contributes to the increase in transcriptional activity, since the reporter activity is well above that conveyed by the ERb homodimer (Figure 3c , compare gray bars of central panels with left and right hand panels). To exclude that this observation was due to increased amounts of ERb, we performed a corresponding experiment in the absence of ERa without detecting any alterations in response to 20 nM of genistein (Figure 3d ).
Differential responses to ER agonists and tamoxifen, but not transcriptional magnitude, are primarily mediated by the AF-2
Recent studies performed by us and others indicate functional dierences between the two ER subtypes. Comparisons between the amino acid sequences of the dierent functional domains reveal almost identical DNA binding domains, striking resemblance in helix 12 and E 2 -binding regions of the LBD, but low degree of conservation in the A/B domain containing the ligand independent AF-1 and in the less well characterized hinge domain positioned between the DBD and the LBD. The AF-1 of ERa has been demonstrated both to act independently in the absence of ligand, but also cooperatively together with the ligand activated AF-2 (Berry et al., 1990; Tzukerman et al., 1994) . A recent study using A/B domain substituted ER chimeras supported previous observations that agonistic response of ERa to tamoxifen is relying on the AF-1 . To be able to distinguish between the activity of AF-1 and AF-2 of the two ER subtypes, we generated chimeric receptors where the hinge domain (D), the LBD (E) and the F domain of ERa and ERb respectively, were linked to the DBD of the yeast factor Gal4 (Figure 4a) . These constructs allowed studies of the activity of the AF-2 of each ER subtype without interference from the AF-1. The Gal4-aDEF and Gal4-bDEF chimeras were cotransfected together with a luciferase reporter gene construct containing Gal4 binding-sites into 293 cells which were subsequently treated with dierent concentrations of E 2 (Figure 4b) . In contrast to the wild type receptors, the ERa chimera showed only a slightly more potent transcriptional response compared to the ERb chimera. However Gal4-bDEF, in analogy to wild type ERb was poorly activated by E 2 levels below 1 nM (Figure 4b , compare light gray bars and black bars). Co-expression of both receptor chimeras in 1 : 1 ratio resulted in a reduced response to 0.1 nM E 2 compared to Gal4-aDEF.
When tamoxifen was used together with E 2 , the activity of Gal4-bDEF was antagonized at lower concentrations of tamoxifen compared to Gal4-aDEF, resembling the results obtained with the full length Figure 2 ERa/ERb co-expression enhances the antagonistic eects of tamoxifen. 293 cells co-transfected with the EREluciferase reporter and ERa and/or ERb expressing plasmids as described in Figure 1 , were treated with increasing concentrations of tamoxifen in combination with 1 nM E 2 . The eects of tamoxifen in combination with E 2 on the transcriptional activity of ERa (a) or ERb homodimers (b) or co-expressed ERa/ERb (c) were assessed. Data is presented as % activity+s.d., where reporter activity at 1 nM of E 2 was arbitrarily set to 100 for each receptor (a and b), or as mean of fold induction+s.d., where activity of reporter plasmid alone with no hormone treatment was arbitrarily set to 1 (c). Data represents experiments performed in duplicates at least three times receptors in the same cellular context (Figure 4c , compare black bars of most left hand panel with most right hand panel). Moreover, 1 mM, but not 100 nM, tamoxifen more strongly antagonized the activity of the Gal4-aDEF in comparison to wild type ERa (compare striped and black bars of the left hand panel of Figure  4b with Figure 2a ). Co-expression of Gal4-aDEF and Gal4-bDEF resulted in intermediate reporter activity at 100 nM tamoxifen. Finally, identical experiments were carried out in the presence of increasing concentrations of genistein (Figure 4d , cells treated with 1 nM of E 2 were included to enable comparison of reporter activity levels). Gal4-bDEF induced reporter activity at 20 nM of genistein whereas Gal4-aDEF did not, similar to what was observed with the full length receptors, thus demonstrating that the selective response to low concentrations of genistein is determined by the ERb-LBD.
Co-expression of both chimeric proteins resulted in an intermediate response at 20 nM genistein clearly contrasting to the enhanced activity obtained with full length receptors (Figure 3c ), which indicates that the response to 20 nM genistein by co-expressed ERs involves the N-terminal parts of the receptors.
Discussion
Heterodimerization between steroid receptors represents a relatively recently discovered phenomenon. Heterodimerization between the glucocorticoid and mineralocorticoid receptors has been suggested to contribute to tissue speci®c actions of glucocorticoids (Trapp et al., 1994) . In addition, the androgen receptor and the glucocorticoid receptor have been shown to mutually interfere with each other's functions through the formation of heterodimeric complexes (Chen et al., 1997) . The ERs have been demonstrated to form functional heterodimeric complexes in several studies, but the consequences of ER The observations presented here demonstrate that co-expression of ERs in¯uences cellular responses to both agonists and antagonists. ERb displays a weaker transcriptional potency in this cellular context compared to ERa, and is shown to require higher concentrations of E 2 for full activity. Co-expression experiments demonstrate that ERb has the ability to inhibit the activity of ERa at E 2 concentrations below the ERb activity threshold level. This probably occurs as a consequence of the formation of heterodimeric complexes between ERa and ERb. Alternatively, the changes in reporter activity could result from transcriptional interference of the respective homodimers. However, it is dicult to envision that ERb homodimers which are not transcriptionally active at E 2 levels below 1 nM, would still be able to compete more eciently for binding to the ERE-containing reporter than ligand-activated ERa homodimers.
Furthermore, we show that co-expression of ERa and ERb, and treatment with tamoxifen increase the antagonistic eect in an ERb dose-dependent manner. Again, ER heterodimerization appears to be the most logical mechanism to explain these observations, since ERb homodimers antagonized by tamoxifen would be unlikely to be able to compete with activated ERa. Taken together these results indicate that ERa/ERb heterodimeric complexes can utilize the full capacity of the ERa transactivation function but only when ERb is fully active. Strikingly, ERa does not reciprocally inhibit ERb activity under reverse conditions, as our results with genistein demonstrate. Instead, transcriptional activity in response to genistein is enhanced when ERa and ERb are co-expressed to levels which could not be obtained with either receptor alone. This intriguing observation suggests that co-localization of ERa and ERb may aect estrogen signaling properties in a manner that cannot be predicted solely from studies of ER homodimers.
The Gal4 chimeric proteins which lack the AF-1 domains demonstrate similar characteristics in the responses to dierent concentrations of E 2 , tamoxifen and genistein as do the full length receptors, suggesting that selectivity in transcriptional activity induced by dierent agonists and antagonists are determined by inherent dierences between ERa and ERb in the respective LBDs. Furthermore, we observed only minor dierences in transcriptional activity between the individual ERa or ERb LBD when fused to the Gal4 DBD, in sharp contrast to our observations with full length receptors where the activity of ERb was merely 40% compared to ERa. This observation indicates that the dierences in activity between ERa and ERb in this cellular context largely depend on the N-terminal AF-1 domains, where the ERa AF-1 makes a signi®cantly higher contribution to the transcriptional activity of ERa than ERb AF-1 does to the activity of ERb. Coexpression of Gal4-aDEF and Gal4-bDEF at conditions unfavorable to one or the other ER subtype resulted in intermediary reporter activity which is in agreement with observations by Tremblay et al. (1999) that a/b heterodimeric complexes were transcriptionally active when only one subunit was able to bind ligand although to a lesser degree than with both subunits ligand-bound.
Taken together these results suggest that the magnitude of the transcriptional response by ERa homodimers as well as putative a/b heterodimeric complexes in this cellular background, is signi®cantly in¯uenced by the N-terminal part of in particular ERa, whose AF-1 to a high degree contributes to the transcriptional response. The AF-1 of ERb, on the other hand, appears to have only a minor eect on the transcriptional activity, which is in agreement with previous observations by others. Furthermore, part of the resistance to tamoxifen antagonism demonstrated by wild type ERa, seems to be due to the agonistic eect which is primarily mediated via the ERa AF-1, as 1 mM tamoxifen antagonized the E 2 -induced activity of Gal4-aDEF more strongly compared to full length ERa. The activity of ERa AF-1 has been demonstrated to act in synergy with the liganded AF-2 through a physical interaction. Therefore the mechanism by which ERb represses ERa activity could involve modulatory eects on the con®guration of the AF-2/ AF-1 interaction. At E 2 concentrations where ERb AF-2 is not activated or in the presence of tamoxifen, the ERa AF-1 may be repressed by the inactive ERb AF-2. In the presence of genistein at concentrations which preferentially activates ERb, activity of the strong ERa AF-1 is supported, thus explaining the high transcriptional response in the presence of both ERa and ERb compared to either receptor alone. This would imply intermolecular contacts between the AF-1 of one subunit and AF-2 of the second subunit taking place within the heterodimeric complex, a notion which needs to be experimentally con®rmed. This hypothesis is however further supported by the observation that co-expression of the Gal4-fusion proteins lacking the AF-1, only gave an intermediate response to 20 nM genistein. The N-terminus of ERa has been shown to interact with the co-activator GRIP1 in addition to the classical interaction via the AF-2 (Webb et al., 1998) . It is possible that ERb may interfere with this interaction or with binding to other obligate factors, or alternatively inhibit release of repressors. Dierences in the populations of co-factors may contribute to cell type speci®c dierences in ER activity and may explain why other studies carried out in dierent cell systems have generated other results.
We conclude that in certain cellular backgrounds ERb has the ability to dominantly regulate the activity of the a/b heterodimer both positively (genistein) and negatively (low concentrations of E 2 and tamoxifen), perhaps through modi®cation of the activity of ERa AF-1. Furthermore, the concentration-dependent responses to both agonists and antagonists but not the magnitude of transcriptional activity, displayed by the ERs, are largely determined by regions located Cterminally of the DBDs and cannot be explained solely by dierences in the N-terminal transactivation domains. Our observations indicate that tissue selective responses to estrogen agonists and antagonists may depend on the expression and relative levels of each ER subtype.
It should be noted that all experiments described in here have been performed with the 485 aa so called short form of ERb (lacking an N-terminal extension). In view of our observations that the responses to E 2 , genistein and tamoxifen are essentially determined by the respective DEF domains, we predict that in this cell system the longer forms of ERb would be interchangeable with the short form.
To date, information of ERb expression at the protein level is limited. A recent study describes coexpression of ERa and ERb protein in mouse mammary gland at dierent developmental stages (Saji et al., 2000) . ERb protein has also been demonstrated to be expressed in rat cardiac myocytes and ®broblasts where ERa is also present (Grohe et al., 1997 (Grohe et al., , 1998 . ERb protein expression in hypothalamic parts of the rat brain appears to cooincide with ERa expression (Li et al., 1997) . Heterodimerization between ERs is therefore likely to occur also in vivo.
Estrogen levels vary in females during the menstrual cycle, pregnancy and at menopause. These¯uctuations may in¯uence the estrogenic activity in tissues containing ERb. Tissues expressing predominantly ERb could be expected to be resistant to low levels of E 2 with respect to regulation of ERE-containing genes. The antiestrogenic eects of tamoxifen on ERE regulated genes may also prove to be more pronounced in tissues that express ERb, a notion which may in the future need to be considered in the endocrine treatment of breast cancer. ERb expression may also amplify the agonistic eect of the iso¯avonoid genistein in tissues that also express ERa. The intake of phytoestrogens vary geographically and the population in areas where the dietary content of genistein and related compounds is high, also appears to have a lower incidence of breast cancer (Kurzer and Xu, 1997) . High dietary content of phytoestrogens has therefore been proposed to be a protective factor against the development of breast tumors (Ingram et al., 1997) . Whether ERb, which shows a higher anity for several phytoestrogenic compounds , participates in the putative cancer preventive actions of phytoestrogens remains to be determined. The concentrations of genistein required for activation of ERs and in particular ERb are well within the range of what can be measured in the circulation of individuals on a diet rich in iso¯avonoids. The presence of ERb protein and mRNA in normal human breast tissue as well as in tumor samples suggests a putative role for ERb in the development of breast cancer (Dotzlaw et al., 1999; Leygue et al., 1998; Sasano et al., 1999; Speirs et al., 1999) . Measurement of ERa has long been used as a diagnostic tool in the clinical evaluation of breast tumors. Clearly, assessment of the role of ERb as a prognostic factor in breast cancer, and in the outcome of endocrine treatment is an important issue that needs to be investigated.
Materials and methods
Plasmid constructs
Wild type hERa and mERb (N.B., the 485 aa so called short form of mERb) in pSG5 vectors and the 26ERE-TK-Luc reporter construct have been described previously (Pettersson et al., 1997) . Gal4-ERa-LBD was generated through cutting of MOR101 (Hillier et al., 1989) with restriction endonucleases FspI and BamHI and insertion of the resulting fragment into pCMX-Gal4 (Perlmann et al., 1996) cut with EcoRV and BamHI. For the Gal4-ERb, pTKS-mERb (Pettersson et al., 1997) was cut with BamHI and the fragment inserted into the BamHI site of pCMX-Gal4. The Gal4-TK-Luc reporter gene has been described before (Forman and Evans, 1995) .
Cell culture and transient co-transfection assays
Human embryonic kidney 293 cells were routinely maintained in a 1 : 1 mix of DMEM (Gibco-BRL) and Ham's Nutrient mixture F12 (F12, Gibco-BRL) containing 7.5% fetal bovine serum (FBS, Gibco-BRL), 0.5% non-essential amino acids (NEA, Gibco-BRL), 1% L-glutamine (Gibco-BRL) and 1% penicillin-streptomycin (PEST, 100 U penicillin/ml and 100 mg streptomycin/ml, Gibco-BRL). 17b-estradiol, tamoxifen and genistein were purchased from Sigma. Cells were seeded in 24-well plates 18 h before transfection. Transient transfections were carried out using Lipofectin transfection reagent (Gibco-BRL) according to the manufacturer's description in a serum-and antibiotic-free mixture of 1 : 1 of F12 and phenol-red free DMEM supplemented with 0.5% NEA and 1% L-glutamine. The optimal amounts of ERa or ERb expressing plasmids for the transfections were carefully determined and 5 ± 30 ng were found to give maximal transcriptional eciency. For each co-transfection experiment 100 ng of the 26ERE-TK-Luc reporter plasmid and 10 ng of pSG5-hERa or pSG5-mERb respectively, or 10 ng of pSG5-hERa together with 5, 10 or 15 ng of pSG5-mERb were used as indicated in the ®gure legends. All plasmid concentrations were equalized with the parental pSG5 vector. Five ng of a CMV-b-galactosidase expression plasmid were included as an internal control of transfection eciency. The transfection medium was changed after 18 h to a phenol-red free mixture of F12 and DMEM supplemented with 5% dextran coated charcoal-treated FBS, 0.5% NEA, 1% L-glutamine and 1% PEST. E 2 , tamoxifen, genistein or vehicle (0.1% ethanol) were added simultaneously. Cells were then incubated at 378C for 24 h. The cells were lysed in 25 mM Tris-Ac, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 2 mM DTT. Luciferase activity was determined using the GenGlow system (Bio Orbit). The b-galactosidase internal control was assayed with the Galacto-Light luminescence kit (Perkin Elmer).
For the studies of chimeric receptors, 75 ng of the Gal4-TK-Luc reporter construct were used together with 10 ng of Gal4-aDEF or Gal4-bDEF, alone or in combination. The transfections, hormone treatment and analysis were carried out as described above.
Data are presented as fold induction, or as per cent of fold induction of luciferase activity corrected for the internal standard as indicated in ®gures and in each case represents the mean+s.d. of at least three independent experiments performed in duplicates. Luciferase activity obtained with cells transfected with the luciferase reporter plasmid, relevant for each experiment (26ERE-TK-Luc or Gal4-TK-Luc), together with the parental empty expression vectors, was arbitrarily set to one.
